Cargando…
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study
BACKGROUND: Severe exacerbations requiring hospitalization contribute a substantial portion of the morbidity and costs of chronic obstructive pulmonary disease (COPD). Triple therapy (inhaled corticosteroid + long-acting β-agonist + long-acting muscarinic antagonist) is a recommended option for pati...
Autores principales: | Evans, Kristin A, Pollack, Michael, Portillo, Edward, Strange, Charlie, Touchette, Daniel R, Staresinic, Anthony, Patel, Sushma, Tkacz, Joseph, Feigler, Norbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372961/ https://www.ncbi.nlm.nih.gov/pubmed/36427341 http://dx.doi.org/10.18553/jmcp.2022.28.12.1366 |
Ejemplares similares
-
PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation
por: Tkacz, Joseph, et al.
Publicado: (2022) -
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
por: Strange, Charlie, et al.
Publicado: (2023) -
Characteristics of initiators of budesonide/glycopyrrolate/formoterol
for treatment of chronic obstructive pulmonary disease (COPD) in the United
States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023) -
Alexander Monro (Primus)
Publicado: (1926) -
PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
por: Criner, Gerard, et al.
Publicado: (2023)